Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

This article was originally published in PharmAsia News

Executive Summary

Takeda submitted an NDA for its dipeptidyl peptidase-4 inhibitor alogliptin (SYR-322) for type 2 diabetes Dec. 27, potentially positioning the Japanese pharma to be second to market with a drug in the class

You may also be interested in...



Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown

Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA

Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown

Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA

Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore

TOKYO - Takeda Pharmaceutical said Sept. 24 its U.S. R&D subsidiary, Takeda Global Research & Development Center, had applied to the U.S. Food and Drug Administration for approval to market an alogliptin/Actos combination tablet for the treatment of type 2 diabetes

Related Content

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel